GMA 301


Endothelin receptor A/endothelin-1 axis is associated with pulmonary artery hypertension (PAH) and has been targeted for the treatment of PAH.  GMA301 is a humanized monoclonal antibody against endothelin receptor A, may become the first long-lasting PAH drug with better efficacy and less adverse effects.


GMA301 is about to start phase 1 clinical testing in Australia.